STANDARD INFUSION1
- Administer only as an intravenous (IV) infusion
- Do not administer as an intravenous push or bolus
- Premedicate patients with an antihistamine and acetaminophen prior to dosing
- Pneumocystis jiroveci pneumonia (PCP) and anti-herpetic viral prophylaxis is recommended for patients with CLL during treatment and for up to 12 months following treatment as appropriate
- Depending on the severity of the infusion reaction and the required interventions, temporarily or permanently discontinue RITUXAN
- Resume infusion at a minimum 50% reduction in rate after symptoms have resolved
- Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion reactions as needed
- Closely monitor the following patients: those with preexisting cardiac or pulmonary conditions, those who experienced prior cardiopulmonary adverse reactions, and those with high numbers of circulating malignant cells (≥25,000/mm3)
- See BOXED WARNING, DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS sections of the full Prescribing Information